Immune-based combination therapy for metastatic kidney cancer

Immune-based combination therapy for metastatic kidney cancerImmune-based combination therapy for metastatic kidney cancer, Published online: 16 April 2019; doi:10.1038/s41581-019-0149-0New data from the JAVELIN Renal 101 and KEYNOTE-426 trials provide evidence that immune-based combination therapy has superior efficacy to sunitinib monotherapy in patients with advanced renal cell carcinoma. The new findings raise important questions regarding the optimum choice of combination therapy for these patients.
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Source Type: research